Close Menu

    Subscribe to Updates

    Get the latest news information from worldwide businesses.

    What's Hot

    Adequate Keratinized Mucosa Linked to Lower Peri-Implantitis Risk: Study

    June 8, 2026

    Hackers likely hijacked over 20,000 Instagram accounts with Meta’s AI chatbot

    June 8, 2026

    Eventbrite and Vimeo owner Bending Spoons files to go public

    June 8, 2026
    Facebook Instagram YouTube LinkedIn X (Twitter)
    Trending
    • Adequate Keratinized Mucosa Linked to Lower Peri-Implantitis Risk: Study
    • Hackers likely hijacked over 20,000 Instagram accounts with Meta’s AI chatbot
    • Eventbrite and Vimeo owner Bending Spoons files to go public
    • India gets EU approval to export aquaculture products, eggs, honey beyond September
    • Adani Ports secures 10-year marine services deal for Argentina’s first LNG export project – The Economic Times Video
    • ‘I have no experience with investing’: I inherited $2,000. I’m 42 with two children. What should I do with this money?
    • ‘Last year we exported Rs 35,000 crore components to China’: Ashwini Vaishnaw
    • ‘Meetings may soon be held in a car’: BJP mocks INDIA bloc huddle over missing members | India News
    Newspublicly
    • About Us
    • Advertise & Partner with us
    • Pitch Your Story
    • Contact Us
    Facebook Instagram LinkedIn X (Twitter)
    Subscribe
    • Home
    • World News
      • Asia
      • India
      • USA
      • UK & Europe
      • Middle East
    • Economy & Business
      • Global Economy
      • Corporate & Industry
      • Finance & Markets
      • Policy & Trade
    • Technology
      • Gadgets & Devices
      • Software & Apps
      • AI & Machine Learning
      • Robotics & Automation
    • Health & Medicine
      • Fitness & Nutrition
      • Research & Innovation
      • Disease & Treatment
      • Doctors, Clinics & Patient Care
    • Travel & Tourism
    • Automobile
      • Electric & Hybrid Vehicles
      • Auto Industry Insights
    • Sports
    • More
      • Education
      • Real Estate
      • Environment & Climate
      • Space & Astronomy
      • War & Conflicts
    Newspublicly
    Home»Health & Medicine»Fitness & Nutrition»Mayim Bialik on GLP-1 Drug Reaction
    Fitness & Nutrition

    Mayim Bialik on GLP-1 Drug Reaction

    AdminBy AdminJune 8, 2026No Comments5 Mins Read0 Views
    Share
    Facebook Twitter LinkedIn Copy Link WhatsApp


    5 min readNew DelhiJun 8, 2026 07:00 PM IST

    The Big Bang Theory’s Mayim Bialik has opened up about a severe reaction she experienced after taking a shot of the lowest dose of a synthetic GLP-1. In a personal essay, Bialik revealed that a single injection triggered weeks of debilitating gastrointestinal symptoms, including diarrhoea, cramping, bloating, nausea, and dehydration. She said she was prescribed the drug not primarily for weight loss, but because doctors believed it might help ease inflammation linked to her autoimmune condition, Graves’ disease.

    “GLP-1s have helped people in serious need. Of that I am certain. But nobody talks much about what happens when it goes wrong. I took one shot of the lowest dose of a synthetic GLP-1, and to say I had an adverse reaction would be somewhat of an understatement. Explosive, uncontrollable diarrhea. Sulfur burps so violent they left me afraid to open my mouth in public. Sneezing attacks every time I tried to eat or drink—which apparently has a name, snatiation. Cramping. Bloating. Full-body aching, as though I had the flu. And an inability to keep down even small sips of water without sprinting to the bathroom with yet more explosive diarrhea. More than three times, I didn’t make it,” she wrote in The Free Press.

    Her account has raised concern around the safety profile of GLP-1 medications, their expanding use beyond weight management, and how patients can distinguish expected side effects from potentially serious adverse reactions.

    DISCLAIMER: This article is based on information from the public domain and/or the experts we spoke to. Always consult your health practitioner before starting any routine.

    How common are severe reactions to GLP-1 drugs?

    GLP-1 receptor agonists, including semaglutide and tirzepatide, have become increasingly popular for managing obesity and type 2 diabetes. While gastrointestinal side effects are well recognised, experts say reactions as severe as the one described by Bialik are uncommon. “Many users experience mild to moderate nausea, diarrhoea, vomiting, abdominal discomfort, or constipation, particularly when starting treatment or increasing the dose,” explains Dr Sandeep Kharb, Senior Consultant – Endocrinology, Asian Hospital. “However, the kind of serious response described by Mayim Bialik, involving explosive diarrhoea, inability to keep fluids down, and dehydration requiring medical attention, is much less common.”

    According to Dr Kharb, clinicians become concerned when symptoms move beyond temporary discomfort and begin to cause physiological consequences such as dehydration, electrolyte imbalances, or nutritional compromise.

    When do side effects become a medical emergency?

    Dr Kharb says patients should seek urgent medical assessment if they experience:

    Story continues below this ad

    • An inability to keep fluids down for more than 24 hours
    • Symptoms of dehydration, such as dizziness, fainting, rapid heartbeat, dry mouth, or reduced urination
    • Severe or persistent abdominal pain
    • Repeated vomiting
    • Blood in the stool
    • Weakness, confusion, or palpitations that may indicate electrolyte imbalance
    • Signs of an allergic reaction, including facial swelling, breathing difficulty, or a widespread rash

    “These situations are rare, but severe gastrointestinal symptoms can sometimes signal complications such as pancreatitis, gallbladder disease, bowel obstruction, or profound dehydration requiring hospital treatment,” he says.

    Can GLP-1 drugs help autoimmune conditions such as Graves’ disease?

    “There is growing scientific interest in the anti-inflammatory properties of GLP-1 receptor agonists,” says Dr Kharb. “Laboratory studies and early clinical observations suggest these drugs may influence immune-cell activity and inflammatory pathways.”

    However, he cautions that the science remains preliminary. “This remains an area of emerging research rather than an established medical indication,” Dr Kharb notes. “There are currently no major clinical guidelines recommending GLP-1 drugs as standard treatment for Graves’ disease, and there are no large randomised controlled trials specifically evaluating autoimmune outcomes.”

    While the biological rationale is promising, experts stress that patients should not assume benefits seen in metabolic diseases will automatically translate to autoimmune conditions.

    Where should doctors draw the line between ‘normal’ and dangerous side effects?

    According to Dr Kharb, the distinction depends on three key factors: severity, duration, and impact on daily functioning. Expected side effects typically include:

    Story continues below this ad

    • Mild nausea
    • Feeling full sooner than usual
    • Occasional diarrhoea
    • Mild constipation
    • Temporary appetite suppression

    “These symptoms often occur during the first few weeks of treatment and tend to improve as the body adapts,” he says. The situation changes when symptoms persist despite dose adjustments, interfere with eating or drinking, cause clinically significant dehydration, lead to unexpected weight loss, require emergency care, or disrupt everyday activities.

    “In practical terms, if a patient cannot stay hydrated, develops severe abdominal pain, or experiences persistent vomiting or diarrhoea, clinicians should no longer treat the reaction as a routine adjustment effect,” says Dr Kharb. “At that point, it is important to evaluate for serious complications or medication intolerance.”

    DISCLAIMER: This article is based on information from the public domain and/or the experts we spoke to. Always consult your health practitioner before starting any routine. 





    Source link

    Author

    • Admin

      NewsPublicly.com is News & Articles Platform that creating SEO-focused articles on travel, lifestyle, and digital trends.

    Admin
    • Website

    NewsPublicly.com is News & Articles Platform that creating SEO-focused articles on travel, lifestyle, and digital trends.

    Related Posts

    Saba Azad debunks pregnancy myths

    June 7, 2026

    How to Get 120g of Protein Daily on a Vegetarian Diet Without Supplements

    June 7, 2026

    ‘I’m gluten-free, dairy-free and also egg-free’

    June 7, 2026
    Leave A Reply Cancel Reply

    Demo
    Top Posts

    The Blue Moon rises on May 30— Where and when to see the second full moon of the month

    May 30, 202640 Views

    New SOCOM rifle allows barrel swapping and cartridge changes

    June 1, 202632 Views

    “Inside Gemini Robotics 1.5: How Robots Learn to Reason & Act

    November 22, 202525 Views

    525 pounds of cocaine seized after Nebraska K9 alerts troopers on I-80

    May 28, 202624 Views
    Don't Miss

    Adequate Keratinized Mucosa Linked to Lower Peri-Implantitis Risk: Study

    June 8, 20261 Min Read0 Views

    Adequate Keratinized Mucosa Linked to Lower Peri-Implantitis Risk: Study We use cookies for analytics, advertising…

    Hackers likely hijacked over 20,000 Instagram accounts with Meta’s AI chatbot

    June 8, 2026

    Eventbrite and Vimeo owner Bending Spoons files to go public

    June 8, 2026

    India gets EU approval to export aquaculture products, eggs, honey beyond September

    June 8, 2026
    Stay In Touch
    • Facebook
    • Twitter
    • Instagram
    • YouTube
    • LinkedIn
    • WhatsApp

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    Demo
    NEWSPUBLICLY
    Facebook X (Twitter) Instagram LinkedIn

    Home

    • About Us
    • Leadership
    • Advertise & Partner With Us
    • Pitch Your Story
    • Media Kit & Pricing
    • Career
    • FAQs

    Guidelines

    • Editorial & Submission
    • Partnership
    • Advertising & Sponsor
    • Intellectual Property Policy
    • Community & Comment
    • Security & Data Protection
    • Send Your Opinion

    Quick Links

    • Cookie Policy
    • Payment & Billing Terms
    • Refund & Cancellation
    • Copyright Policy
    • Complaint & Support
    • Sitemap
    • Contact Us

    Subscribe Us

    Get the latest news and updates!

    Copyright © 2026 Newspublicly (DIGITALIX COMMUNICATION). All Rights Reserved.
    • Privacy Policy
    • Terms of Use
    • Disclaimer